The SUSTAIN 6 trial demonstrated that semaglutide reduced cardiovascular events by 26% and showed improvements in blood pressure control
It remains one of the few endogenous peptides whose receptor target has not been definitively characterized, making it an active subject of mechanism-of-action research
Semaglutide, the active ingredient in Wegovy, has been shown in trials to reduce cardiovascular risk, not just weight
Vitamin C, found in citrus fruits, berries, kiwis, and peppers, has been linked to better sperm count and motility
The peptide's agonist activity at MC4R receptors in the hypothalamus suppresses hunger signaling by mimicking alpha-MSH, the endogenous melanocortin that regulates energy balance
Kentucky Medicaids current prior-authorization criteria exclude drugs prescribed for weight loss